Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study

Meltzer, Eli O.; Ratner, Paul H.; McGraw, Thomas

doi:10.1016/j.jaip.2015.05.007

Cited by 38 publications

(30 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…409 This has promoted substitution of oral phenylephrine for pseudoephedrine in many allergy and cold and cough remedies. However, oral phenylephrine has been demonstrated to be ineffective at reducing nasal congestion at doses up to 40 mg. [410][411][412] Pseudoephedrine can result in adverse effects such as insomnia, loss of appetite, irritability, and palpitations. 413 Elevation of blood pressure after taking an oral decongestant is very rarely noted in normotensive patients and only occasionally in patients with controlled hypertension.…”

Section: Oral Decongestantsmentioning

confidence: 99%

Rhinitis 2020: A practice parameter update

Parameters

Contributors

2020

Journal of Allergy and Clinical Immunology

Self Cite

235

189

View full text Add to dashboard Cite

Section: Oral Decongestantsmentioning

confidence: 99%

Rhinitis 2020: A practice parameter update

Parameters

Contributors

2020

Journal of Allergy and Clinical Immunology

Self Cite

235

189

View full text Add to dashboard Cite

“…Comparably, this study demonstrated that microcurrent treatment analgesia lasted up to 6 hrs after the first treatment. Research on the efficacy of decongestant medications has shown that phenylephrine can reduce nasal congestion severity by − 7.1% to − 25% and regulated formulations of pseudoephedrine can reduce congestion symptoms by approximately − 21.7% (Horak et al 2009;Meltzer et al 2015). Fluticasone propionate, one of the more efficacious drug therapies available for nasal congestion, has been reported to reduce congestion symptoms by − 33.6% to − 47% depending on the study (Nathan et al 2005;Ratner et al 2002).…”

Section: Discussionmentioning

confidence: 99%

Prospective trial examining safety and efficacy of microcurrent stimulation for the treatment of sinus pain and congestion

2019

View full text Add to dashboard Cite

Background: Inflammation and swelling of the sinus and nasal mucosa are commonly caused by viral infection, bacterial infection, or exposure to allergens and irritants. Sinonasal inflammation can cause symptoms of nasal congestion, facial pressure, and rhinogenic facial pain or "sinus pain". A previous randomized controlled study demonstrated that acute treatment with non-invasive periorbital microcurrent stimulation resulted in a rapid and clinically meaningful reduction in self-report of sinus pain that significantly outperformed sham control treatment.Here, we assessed the acute durability of microcurrent pain relief and longitudinal effects of 4 weeks of daily microcurrent treatment in patients presenting with sinus pain.Methods: Thirty subjects with moderate facial pain (numeric rating scale ≥5) attributed to self-reported sinonasal disease were enrolled in a single-arm, prospective interventional study. At enrollment, subjects were given a microcurrent treatment device and written instructions and self-administered the device to the bilateral periorbital regions for 5 mins. Subjects were instructed to treat themselves at home once daily and up to four times daily as needed for 4 weeks. Pain was measured both acutely and weekly during the 4 weeks of treatment using the numeric rating scale. Congestion and medication use data were collected weekly using the Congestion Quantifier 7 (CQ7) and medication diary, respectively. Results: Thirty patients were enrolled and completed the study. Microcurrent therapy rapidly reduced post-treatment numeric rating scale for pain by − 1.2 at 10 mins (p = 0.0076), − 1.6 at 1 hr (p = 0.0007), − 1.9 at 2 hrs (p < 0.0001), − 2.1 at 4 hrs (p < 0.0001), and − 2.1 at 6 hrs (p < 0.0001). With daily microcurrent treatment, numeric rating scale for pain was reduced over 4 weeks by − 1.3 (− 20.1%) after 1 week (p = 0.0018), − 2.1 (− 32.1%) after 2 weeks (p < 0.0001), − 2.4 (− 36.6%) after 3 weeks (p < 0.0001) and − 2.9 (− 43.3%) after 4 weeks (p < 0.0001). For subjects who enrolled with moderate or worse congestion, mean congestion scores (CQ7) were reduced by − 4.2 (− 22.0%) after 1 week (p < 0.0001), − 5.8 (− 33.0%) after 2 weeks (p < 0.0001), − 7.2 (− 37.4%) after 3 weeks (p < 0.0001) and − 8.6 (− 44.3%) after 4 weeks (p < 0.0001) of microcurrent treatment.Conclusion: Self-administered periorbital microcurrent treatment given at home was efficacious in significantly reducing moderate sinus pain for up to 6 hrs and significantly reducing moderate pain and congestion over 4 weeks of daily use. Microcurrent therapy was found to be safe with only minor side effects that resolved without intervention. Trial registration: ClinicalTrials.gov, NCT03888274. Registered 25 March 2019. Retroactively registered, https:// clinicaltrials.gov/ct2/show/NCT03888274.

show abstract

“…Многие клиницисты предпочитают начинать терапию с будесонида в связи с тем, что он относится к препаратам категории В и имеет большую доказательную базу по сравнению с другими ингаляционными ГКС, использующимися для лечения аллергического ринита [8]. В настоящее время безопасными для применения в I триместре признаны также флутиказон и мометазон [9].…”

Section: акушерствоunclassified

Current treatment approach to allergic disorders in pregnancy

Боровкова¹,

Borovkov²,

Koroleva³

et al. 2020

Russian Journal of Woman and Child Health

View full text Add to dashboard Cite

The article addresses the results of systematic review of current published data on management strategy of pregnancy associated with allergic disorders. Difficulties in the diagnosis are accounted for by physiological changes and failure to perform standard testing. All diagnostic procedures aimed at identifying allergic diseases should be carried out at the stage of pregnancy planning, which is associated with an increased risk of using skin tests and stress tests. Vasomotor rhinitis of pregnancy, allergic rhinitis, sinusitis, and rhinitis medicamentosa are the most common conditions during pregnancy. Their treatment should be started with non-medical therapies, i.e., nasal lavage with salt solutions, inhalations of cromolyn sodium preparations, corticosteroids, and H1 blockers. Treatment for atopic dermatitis includes emollients and oral antihistamines. Topical hydrocortisone formulations (2C) are additional therapies. Allergic reactions do not directly affect the risk of obstetric complications.Keywords: allergy, vasomotor rhinitis, allergic rhinitis, sinusitis, urticaria, dermatosis of pregnancy, corticosteroids, histamine receptor blockers.For citation: Borovkova E.I., Borovkov I.M., Koroleva V.I., Pashchenko A.A. Current treatment approach to allergic disorders in pregnancy. Russian Journal of Woman and Child Health. 2020;3(2):70–76. DOI: 10.32364/2618-8430-2020-3-2-70-76.

show abstract

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study

Cited by 38 publications

References 27 publications

Rhinitis 2020: A practice parameter update

Rhinitis 2020: A practice parameter update

Prospective trial examining safety and efficacy of microcurrent stimulation for the treatment of sinus pain and congestion

Current treatment approach to allergic disorders in pregnancy

Contact Info

Product

Resources

About